KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xenon Pharmaceuticals (XENE) EBIT Margin: 2013-2025

Historic EBIT Margin for Xenon Pharmaceuticals (XENE) over the last 9 years, with Mar 2025 value amounting to -969.84%.

  • Xenon Pharmaceuticals' EBIT Margin was N/A to -969.84% in Q1 2025 from the same period last year, while for Mar 2025 it was -1,730.22%, marking a year-over-year change of. This contributed to the annual value of -1,368.91% for FY2022, which is 94046.00% down from last year.
  • As of Q1 2025, Xenon Pharmaceuticals' EBIT Margin stood at -969.84%, which was up 96.64% from -28,884.85% recorded in Q3 2022.
  • Xenon Pharmaceuticals' 5-year EBIT Margin high stood at -198.14% for Q1 2022, and its period low was -28,884.85% during Q3 2022.
  • For the 1-year period, Xenon Pharmaceuticals' EBIT Margin averaged around -969.84%, with its median value being -969.84% (2025).
  • Over the last 5 years, Xenon Pharmaceuticals' EBIT Margin had its largest YoY gain of 17,035bps in 2022, and its largest YoY loss of 2,853,823bps in 2022.
  • Over the past 3 years, Xenon Pharmaceuticals' EBIT Margin (Quarterly) stood at -664.65% in 2021, then tumbled by 2,853,823bps to -28,884.85% in 2022, then reached -969.84% in 2025.
  • Its EBIT Margin was -969.84% in Q1 2025, compared to -28,884.85% in Q3 2022 and -5,655.78% in Q2 2022.